PEGPH 20

Halozyme Therapeutics, Inc. (NASDAQ: HALO) has developed a new drug called PEGPH 20, which is changing the way pancreatic cancer patients are treated. Helen Torley, Halozyme Therapeutics CEO, was on CNBC Monday to shed more light on the drug and the success it has had. PEGPH 20 "Some...